Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Experimental Hematology & Oncology
Published in: Experimental Hematology & Oncology 1/2013

Open Access 01-12-2013 | Letter to the Editor

T-Cell/Histiocyte-Rich Large B-Cell Lymphoma of the Thyroid

Authors: Satoshi Ichikawa, Yasuaki Watanabe, Kei Saito, Jun Kimura, Ryo Ichinohasama, Hideo Harigae

Published in: Experimental Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare subtype of diffuse large B-cell lymphoma, and has been reported to mainly affect lymph nodes with advanced Ann Arbor stage. We present a 69-year-old woman with a past history of chronic thyroiditis, who had suffered from rapidly-growing thyroid tumor. No other lymph nodes swelling or extranodal lesions were detected. She promptly underwent surgery with resection of the thyroid tumor, and the diagnosis of THRLBCL was established pathologically. She was successfully treated by standard rituximab-containing chemotherapy. To our knowledge, this is the first case report of THRLBCL exclusively arising in the thyroid.
Appendix
Available only for authorised users
Literature
1.
De Wolf-Peeters C, Delabie J, Campo E, Jaffe ES, Delsol G, et al.: T-cell/histiocyte-rich large B-cell lymphoma. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Edited by: Swedlow SH. Lyon, France: International Agency for Research on Cancer; 2008:238–239.
2.
Weshi AE, Akhtar S, Mourad WA, Ajarim D, Abdelsalm M, Khafaga Y, et al.: T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma 2007, 48: 1764–1773. 10.1080/10428190701559124PubMedCrossRef
3.
Bouadallar R, Mounier N, Guettier C, Molina T, Ribrag V, Thieblemont C, et al.: T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. J Clin Oncol 2003, 21: 1271–1277. 10.1200/JCO.2003.06.046CrossRef
4.
Gregory A, Thompson LDR, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL: Malignant Lymphoma of the Thyroid Gland; A Clinicopathologic Study of 108 Cases. Am J Surg Pathol 2000, 24: 623–639. 10.1097/00000478-200005000-00001CrossRef
5.
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Sakajiri A, Ueda K, et al.: R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma. Exp Hematol Oncol 2012, 1: 30. 10.1186/2162-3619-1-30PubMedCentralPubMedCrossRef
Metadata
Title
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma of the Thyroid
Authors
Satoshi Ichikawa
Yasuaki Watanabe
Kei Saito
Jun Kimura
Ryo Ichinohasama
Hideo Harigae
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2013
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/2162-3619-2-1

Other articles of this Issue 1/2013

Experimental Hematology & Oncology 1/2013 Go to the issue

Research

In vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines

Case report

Hairy cell leukemia in kidney transplantation: lesson from a rare disorder

Case report

Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F

Research

Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia

Case report

Utility of hydroxyurea in mast cell activation syndrome

Review

Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits